Prolonged response to trabectedin in a patient with ovarian carcinosarcoma refractory to adjuvant platinum-taxane

Edgar Petru, Vassiliki Kolovetsiou, Tina Idris

Abstract


Background: Carcinosarcoma of the ovary carries an unfavorable prognosis and the optimal chemotherapeutic regimen for this disease is yet to be determined. To the authors´ knowledge, this is the first report of a metastatic ovarian carcinosarcoma successfully treated with trabectedin monotherapy after failure of platinum/taxane-based therapy.

Case report: The case of a platinum-refractory advanced ovarian carcinosarcoma in a 73-year-old female is presented. After initial tumor debulking, the patient received adjuvant carboplatin and paclitaxel. After 2 cycles, tumor progression occurred. The authors speculated that rapid tumor progression occurred as a consequence of regrowth of sarcomatous elements within the carcinosarcoma. This platinum-refractory disease was treated with single-agent trabectedin 1.5 mg/m2 every three weeks. A prolonged partial response for 13 months along with an acceptable safety profile was achieved. During this time, the patient was able to perform her daily activities without restrictions.

Conclusion: Our case suggests that trabectedin monotherapy may represent a viable therapeutic option for patients with platinum-refractory advanced ovarian carcinosarcoma.



Full Text: PDF DOI: 10.5430/jst.v3n3p9

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Journal of Solid Tumors

ISSN 1925-4067(Print)   ISSN 1925-4075(Online)

Copyright © Sciedu Press


To make sure that you can receive messages from us, please add the 'Sciedu.ca' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.